Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Shock. 2021 Jul 1;56(1):65–72. doi: 10.1097/SHK.0000000000001687

Table 1:

Demographics and clinical characteristics of patients with and without shock resolution by 48 hours from enrollment.

Variable Shock resolution (n = 81) Persistent shock (n = 147) P-value

Demographics

Age, years (IQR) 62 (52, 70) 64 (55, 73) 0.26

Male, n (%) 51 (63) 77 (52) 0.12
Female, n (%) 30 (37) 70 (48)

Race
 Black, n (%) 24 (30) 45 (31) 0.91
 Asian, n (%) 2 (2) 3 (2)
 White, n (%) 48 (59) 89 (61)
 Other, n (%) 7 (9) 9 (6)

Ethnicity
 Hispanic, n (%) 5 (6) 7 (5) 0.64

Past medical history

 Diabetes, n (%) 26 (32) 54 (37) 0.59
 Liver disease, n (%) 8 (10) 26 (18) 0.12
 Renal disease, n (%) 8 (10) 26 (18) 0.12

Physiologic variables

 Heart rate, beats per minute (IQR) 94 (82, 107) 102 (88, 115) 0.01
 Respiratory rate, breaths per minute (IQR) 20 (16, 24) 21 (18, 26) 0.12
 Cumulative vasopressor index (IQR) 4 (3, 7.5) 4 (4, 8) 0.001
 Body mass index (IQR) 28 (22, 36) 28 (24, 34) 0.22

Laboratory values

 White blood count, cells/mm3 (IQR) 17 (12, 26) 19 (11, 28) 0.69
 Platelet count, cells/mm3 (IQR) 178 (98, 246) 132 (70, 204) 0.01
 Creatinine, mg/dL (IQR) 1.8 (1.2, 2.7) 2.0 (1.3, 2.9) 0.31
 Total Bilirubin, mg/dL (IQR) 0.9 (0.5, 1.7) 1.4 (0.6, 3.3) 0.007
 Lactate, mmol/L (IQR) 3.1 (2.0, 5) 4.1 (2.7, 7) 0.002

Severity of Illness

 SOFA score 9 (7, 12) 12 (10, 14) <0.001

Co-interventions

 L-carnitine treatment 55 (68) 104 (71) 0.65